Iron-ovotransferrin preparation does not interfere with ciprofloxacin absorption

Franco Pazzucconi, Silvia Barbi, Damiano Baldassarre, Nicola Colombo, Fabio Dorigotti, Cesare R. Sirtori

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Iron supplements can interfere with the bioavailability of a number of drugs, including thyroxine, tetracycline derivatives, penicillamine, methyldopa, levodopa, carbidopa, ciprofloxacin, aid the newer fluoroquinolones. A new iron formulation was tested in which iron ions are bound to ovaltransferrin, a protein that shares more than an 80% similarity with the sequence of human transferrin and, apparently is less likely than the commonly used iron salts to reduce drug absorption. Ciprofloxacin was taken as a model drug, of wide use and restricted range of therapeutic levels, and its absorption was evaluated after the administration of the iron-ovotransferrin complex versus an iron-gluconate formulation high healthy volunteers. At variance with the iron gluconate formulation, which led to a reduction of about 50% of peak serum ciprofloxacin levels (C(max); 1.0 ± 0.2 versus 2.4 ± 0.3 μg/ml; p <0.01) and of the area under the serum concentration-time curve from time 0 to infinity [AUC(0-∞); 10.1 ± 1.1 versus 18.3 ± 1.0 mg · L-1 hr; p <0.01], the iron-ovotransferrin complex caused only modest, non significant changes in absorption with a minimal reduction of-the AUC(0-∞) (17.3 ± 1.0 versus 18.3 ± 1.0 mg L-1 hr; difference not significant) and a nonsignificant decrease in the C(max) (2.2 ± 0.3 versus 2.4 ± 0.3 μg/ml; difference not significant), Iron was also well absorbed from the formulation in the presence of a fatty meal. The very common drug interactions with oral iron preparations can be effectively prevented by the use of the iron-ovotransferrin complex interacting to a minimal extent with a sensitive drug with a reduced margin of efficacy, such as ciprofloxacin.

Original languageEnglish
Pages (from-to)418-422
Number of pages5
JournalClinical Pharmacology and Therapeutics
Volume59
Issue number4
DOIs
Publication statusPublished - Apr 1996

Fingerprint

Conalbumin
Ciprofloxacin
Iron
Pharmaceutical Preparations
Area Under Curve
Methyldopa
Penicillamine
Fluoroquinolones
Transferrin
Tetracycline
Serum
Thyroxine
Drug Interactions
Biological Availability
Meals

ASJC Scopus subject areas

  • Pharmacology

Cite this

Iron-ovotransferrin preparation does not interfere with ciprofloxacin absorption. / Pazzucconi, Franco; Barbi, Silvia; Baldassarre, Damiano; Colombo, Nicola; Dorigotti, Fabio; Sirtori, Cesare R.

In: Clinical Pharmacology and Therapeutics, Vol. 59, No. 4, 04.1996, p. 418-422.

Research output: Contribution to journalArticle

Pazzucconi, Franco ; Barbi, Silvia ; Baldassarre, Damiano ; Colombo, Nicola ; Dorigotti, Fabio ; Sirtori, Cesare R. / Iron-ovotransferrin preparation does not interfere with ciprofloxacin absorption. In: Clinical Pharmacology and Therapeutics. 1996 ; Vol. 59, No. 4. pp. 418-422.
@article{2efa0482b9d449a19e8b482c92a3c9df,
title = "Iron-ovotransferrin preparation does not interfere with ciprofloxacin absorption",
abstract = "Iron supplements can interfere with the bioavailability of a number of drugs, including thyroxine, tetracycline derivatives, penicillamine, methyldopa, levodopa, carbidopa, ciprofloxacin, aid the newer fluoroquinolones. A new iron formulation was tested in which iron ions are bound to ovaltransferrin, a protein that shares more than an 80{\%} similarity with the sequence of human transferrin and, apparently is less likely than the commonly used iron salts to reduce drug absorption. Ciprofloxacin was taken as a model drug, of wide use and restricted range of therapeutic levels, and its absorption was evaluated after the administration of the iron-ovotransferrin complex versus an iron-gluconate formulation high healthy volunteers. At variance with the iron gluconate formulation, which led to a reduction of about 50{\%} of peak serum ciprofloxacin levels (C(max); 1.0 ± 0.2 versus 2.4 ± 0.3 μg/ml; p <0.01) and of the area under the serum concentration-time curve from time 0 to infinity [AUC(0-∞); 10.1 ± 1.1 versus 18.3 ± 1.0 mg · L-1 hr; p <0.01], the iron-ovotransferrin complex caused only modest, non significant changes in absorption with a minimal reduction of-the AUC(0-∞) (17.3 ± 1.0 versus 18.3 ± 1.0 mg L-1 hr; difference not significant) and a nonsignificant decrease in the C(max) (2.2 ± 0.3 versus 2.4 ± 0.3 μg/ml; difference not significant), Iron was also well absorbed from the formulation in the presence of a fatty meal. The very common drug interactions with oral iron preparations can be effectively prevented by the use of the iron-ovotransferrin complex interacting to a minimal extent with a sensitive drug with a reduced margin of efficacy, such as ciprofloxacin.",
author = "Franco Pazzucconi and Silvia Barbi and Damiano Baldassarre and Nicola Colombo and Fabio Dorigotti and Sirtori, {Cesare R.}",
year = "1996",
month = "4",
doi = "10.1016/S0009-9236(96)90110-1",
language = "English",
volume = "59",
pages = "418--422",
journal = "Clinical Pharmacology and Therapeutics",
issn = "0009-9236",
publisher = "Nature Publishing Group",
number = "4",

}

TY - JOUR

T1 - Iron-ovotransferrin preparation does not interfere with ciprofloxacin absorption

AU - Pazzucconi, Franco

AU - Barbi, Silvia

AU - Baldassarre, Damiano

AU - Colombo, Nicola

AU - Dorigotti, Fabio

AU - Sirtori, Cesare R.

PY - 1996/4

Y1 - 1996/4

N2 - Iron supplements can interfere with the bioavailability of a number of drugs, including thyroxine, tetracycline derivatives, penicillamine, methyldopa, levodopa, carbidopa, ciprofloxacin, aid the newer fluoroquinolones. A new iron formulation was tested in which iron ions are bound to ovaltransferrin, a protein that shares more than an 80% similarity with the sequence of human transferrin and, apparently is less likely than the commonly used iron salts to reduce drug absorption. Ciprofloxacin was taken as a model drug, of wide use and restricted range of therapeutic levels, and its absorption was evaluated after the administration of the iron-ovotransferrin complex versus an iron-gluconate formulation high healthy volunteers. At variance with the iron gluconate formulation, which led to a reduction of about 50% of peak serum ciprofloxacin levels (C(max); 1.0 ± 0.2 versus 2.4 ± 0.3 μg/ml; p <0.01) and of the area under the serum concentration-time curve from time 0 to infinity [AUC(0-∞); 10.1 ± 1.1 versus 18.3 ± 1.0 mg · L-1 hr; p <0.01], the iron-ovotransferrin complex caused only modest, non significant changes in absorption with a minimal reduction of-the AUC(0-∞) (17.3 ± 1.0 versus 18.3 ± 1.0 mg L-1 hr; difference not significant) and a nonsignificant decrease in the C(max) (2.2 ± 0.3 versus 2.4 ± 0.3 μg/ml; difference not significant), Iron was also well absorbed from the formulation in the presence of a fatty meal. The very common drug interactions with oral iron preparations can be effectively prevented by the use of the iron-ovotransferrin complex interacting to a minimal extent with a sensitive drug with a reduced margin of efficacy, such as ciprofloxacin.

AB - Iron supplements can interfere with the bioavailability of a number of drugs, including thyroxine, tetracycline derivatives, penicillamine, methyldopa, levodopa, carbidopa, ciprofloxacin, aid the newer fluoroquinolones. A new iron formulation was tested in which iron ions are bound to ovaltransferrin, a protein that shares more than an 80% similarity with the sequence of human transferrin and, apparently is less likely than the commonly used iron salts to reduce drug absorption. Ciprofloxacin was taken as a model drug, of wide use and restricted range of therapeutic levels, and its absorption was evaluated after the administration of the iron-ovotransferrin complex versus an iron-gluconate formulation high healthy volunteers. At variance with the iron gluconate formulation, which led to a reduction of about 50% of peak serum ciprofloxacin levels (C(max); 1.0 ± 0.2 versus 2.4 ± 0.3 μg/ml; p <0.01) and of the area under the serum concentration-time curve from time 0 to infinity [AUC(0-∞); 10.1 ± 1.1 versus 18.3 ± 1.0 mg · L-1 hr; p <0.01], the iron-ovotransferrin complex caused only modest, non significant changes in absorption with a minimal reduction of-the AUC(0-∞) (17.3 ± 1.0 versus 18.3 ± 1.0 mg L-1 hr; difference not significant) and a nonsignificant decrease in the C(max) (2.2 ± 0.3 versus 2.4 ± 0.3 μg/ml; difference not significant), Iron was also well absorbed from the formulation in the presence of a fatty meal. The very common drug interactions with oral iron preparations can be effectively prevented by the use of the iron-ovotransferrin complex interacting to a minimal extent with a sensitive drug with a reduced margin of efficacy, such as ciprofloxacin.

UR - http://www.scopus.com/inward/record.url?scp=0029923883&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029923883&partnerID=8YFLogxK

U2 - 10.1016/S0009-9236(96)90110-1

DO - 10.1016/S0009-9236(96)90110-1

M3 - Article

VL - 59

SP - 418

EP - 422

JO - Clinical Pharmacology and Therapeutics

JF - Clinical Pharmacology and Therapeutics

SN - 0009-9236

IS - 4

ER -